# US 2001/0022963 A1 · Light imaging contrast agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0022963 A1
- Document ID: US20010022963A1
- Status: Published application
- Kind: A1
- Application number: 09/732,917
- Filed: 2000-12-11
- Published: 2001-09-20
- Earliest claimed: 1996-02-02
- Assignees: Nycomed Imaging AS, a Oslo, Norway Corporation
- Inventors: Jo Klaveness; Bjorn Fuglass; Pal Rongved; Edvin Johannesen; Paul Mark Henrichs; Wolfgang Hans Heinrich Gunther; Edward Richard Bacon; John Luke Toner; Gregory Lynn McIntire; Vinay C. Desai
- Web page: https://patentgrep.com/patent/US20010022963A1

## CPC

- A61K 49/001: {Preparation for luminescence or biological staining}
- A61K 49/0015: {Phosphorescence}
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0034: {Indocyanine green, i.e. ICG, cardiogreen}
- A61K 49/0043: {Fluorescein, used in vivo}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0078: {microemulsion, nanoemulsion}
- A61K 49/0082: {micelle, e.g. phospholipidic micelle and polymeric micelle}
- A61K 49/0084: {liposome, i.e. bilayered vesicular structure}
- A61K 49/0433: {containing an organic halogenated X-ray contrast-enhancing agent}
- A61K 49/0461: {Dispersions, colloids, emulsions or suspensions}
- A61K 49/0466: {Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles}
- A61K 49/0485: {Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer}
- A61K 49/223: {Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}
- A61K 49/227: {Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric}
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.

## Claims

### Claim 1

A method of generating an image of the human or non-human animal body by light imaging, characterized in that a physiologically tolerable particulate contrast agent is administered to said body and an image of at least part of said body is generated.

### Claim 2 (depends on 1)

A method as claimed in claim 1 wherein said image is a spatial image.

### Claim 3 (depends on 1)

A method as claimed in claim 1 wherein said image is a temporal image.

### Claim 4 (depends on 1)

A method as claimed in claim 1 wherein said image is generated from light transmitting through at least part of said body.

### Claim 5 (depends on 1)

A method as claimed in claim 1 wherein said image is generated from light reflected from at least part of said body.

### Claim 6 (depends on 1)

A method as claimed in claim 1 wherein said image is generated from fluorescence emitted by said agent.

### Claim 7 (depends on 1)

A method as claimed in claim 1 wherein said image is generated from phosphoresence emitted by said agent.

### Claim 8 (depends on 1)

A method as claimed in claim 1 wherein said image is of vasculature in said body.

### Claim 9 (depends on 1)

A method as claimed in claim 1 wherein said image is of a phagocytic organ in said body.

### Claim 10 (depends on 1)

A method as claimed in claim 1 wherein light is emitted and detected endoscopically.

### Claim 11 (depends on 1)

A method as claimed in claim 1 wherein said body is irradiated with monochromatic light.

### Claim 12 (depends on 1)

A method as claimed in claim 1 wherein the particle size of said particulate agent is from λ/4Π to λ/Π, where λ is the wavelength of said monochromatic light.

### Claim 13 (depends on 12)

A method as claimed in claim 12 wherein said particle size is about λ/2Π.

### Claim 14 (depends on 1)

A method as claimed in claim 1 wherein said particulate agent is not photo-labelled.

### Claim 15 (depends on 14)

A method as claimed in claim 14 wherein said agent comprises gas-microbubbles.

### Claim 16 (depends on 14)

A method as claimed in claim 14 wherein said agent comprises solid or liquid particles.

### Claim 17 (depends on 14)

A method as claimed in claim 14 wherein said agent comprises liposomes.

### Claim 18 (depends on 1)

A method as claimed in claim 1 wherein said particulate agent comprises a photolabel having a molar absorptivity of at least 105 cm−1M−1 and an absorption maximum in the range 300 to 1300 nm.

### Claim 19 (depends on 18)

A method as claimed in claim 18 wherein said particulate agent comprises liposomes.

### Claim 20 (depends on 18)

A method as claimed in claim 18 wherein said particulate agent comprises solid or liquid particles.

### Claim 21 (depends on 18)

A method as claimed in claim 18 wherein said particulate agent comprises solid particles coated with a said photolabel.

### Claim 22 (depends on 18)

A method as claimed in claim 18 wherein said particulate agent comprises micelles.

### Claim 23

A method of manufacturing a particulate contrast agent for in vivo diagnostic light imaging comprising combining a physiologically tolerable particulate material and a medium.

### Claim 24

A method of generating an image of the human or non-human animal body by light imaging comprising manufacturing a particulate contrast agent for in vivo diagnostic light imaging including a physiologically tolerable particulate material, administering the contrast agent to said body, and generating an image of at least part of said body.

### Claim 25

A diagnostic imaging composition comprising a physiologically tolerable particulate agent comprising solid particles coated with a photolabel having a molar absorptivity of at least 105 cm−1M−1 and an absorption maximum in the range 300 to 1300 nm.

### Claim 26

A method of diagnosing diseased states comprising generating an image of the human or non-human animal body by light imaging by in vivo spectroscopy of a physiologically tolerable particulate contrast agent.

### Claim 27 (depends on 1)

A method as claimed in claim 1 wherein said image is generated by a light imaging technique selected from confocal scanning laser microscopy, optical coherence tomography, and laser doppler and laser speckle techniques.

### Claim 28 (depends on 27)

A method as claimed in claim 27 wherein said body is illuminated with light of a wavelength in the range 600 to 1300 nm and said image is generated using directed scattered light of a wavelength in the range 600 to 1300 nm.

### Claim 29 (depends on 28)

A method as claimed in claim 28 wherein the particles of said particulate agent have a mean particle size in the range 600 to 1300 nm.

### Claim 30 (depends on 29)

A method as claimed in claim 29 wherein the coefficient of variation of the particle size of said particles is less than 10%.

### Claim 31 (depends on 27)

A method as claimed in claim 27 wherein said image is an image of a part of said body no more than 1 mm below an exposed or endoscopically accessed surface thereof.

### Claim 32 (depends on 31)

A method as claimed in claim 31 wherein said image is an image of part of the skin.

### Claim 33 (depends on 31)

A method as claimed in claim 31 wherein said image is an image of a part of said body no more than 1 mm below a surgically exposed surface.

### Claim 34 (depends on 27)

A method as claimed in claim 27 wherein said particles are selected from polymer particles, dyestuff particles, and iodinated organic compound particles.
